EBRT Use and Safety with Radium-223 in Patients with CRPC and Bone Metastases from ALSYMPCA - Oliver Sartor

April 13, 2015

*It is recommended to watch this video in full screen for an optimal viewing experience.

EBRT Use and Safety with Radium-223 in Patients with CRPC and Symptomatic Bone Metastases from the ALSYMPCA Trial

Professor Sartor presents results from the ALSYMPCA trial which showed radium-223 significantly reduced the risk of EBRT use for bone pain while significantly improving overall survival (OS). Moreover, concomitant EBRT did not adversely affect radium-223 hematologic safety.

A. Oliver Sartor, MD
Laborde Professor of Cancer Research
Departments of Medicine and Urology
Medical Director of Tulane Cancer Center
Tulane School of Medicine
New Orleans, Louisiana

Bibliographical Information

Dr. Oliver Sartor is the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. He is a medical oncologist with an interest in prostate cancer from both a basic and clinical perspective. He is on the Department of Defense Integration Panel for prostate cancer research and is the chairman-elect of the organization as well as co-editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer. He is also the current medical oncology chair of the Radiation Oncology Treatment Group Genitourinary Cancer Committee. In addition, Dr. Sartor is a SPORE project co-PI at Dana-Farber Cancer Center on a translational project involving the clinical outcomes and consequences of the 8q24 risk alleles. Dr. Sartor's current research interests include clinical trials in advanced prostate cancer with novel agents and novel combinations of agents. His collaborative projects include novel concepts in prostate stem cells and germ line assessment of prostate cancer risk.